JNCI Journal of the National Cancer Institute
Oxford University Press · US · ISSN 00278874
动向摘要
Output rose while average citedness slipped.
Field-weighted citation impact moved from 4.18 to 2.56. Expect lower average citation performance per article than before. Output grew sharply while citation impact fell. If you prioritize citation visibility, weigh this trend in your decision. The share of top-10% cited papers moved from 49.3% to 29.3%. A smaller share of articles now reach the highest cited ranks, so plan dissemination accordingly. Recent titles increasingly carry multicancer · karisma · endoxifen · nrg · folfirinox. If your work matches these emerging terms it may align with recent topical coverage.
引用指标
基于 Scopus 与 OpenAlex 引用图谱。本站不提供 Clarivate 的 JCR 影响因子。
发文量与被引表现
发文量增长时被引表现是否同步。
主题变化
对比近 24 个月(2024-09 – 2026-08)与此前 24 个月(2022-09 – 2024-08)的占比。
- Colorectal Cancer Screening and Detection6.0%→9.5%+3.4%p此前近期
- Cutaneous Melanoma Detection and Management0.0%→3.3%+3.3%p此前近期
- Chemotherapy-induced cardiotoxicity and mitigation0.0%→3.0%+3.0%p此前近期
- Pancreatic and Hepatic Oncology Research0.0%→2.7%+2.7%p此前近期
- Lung Cancer Diagnosis and Treatment0.0%→2.7%+2.7%p此前近期
- Genetic factors in colorectal cancer4.4%→0.0%−4.4%p此前近期
- Cancer Immunotherapy and Biomarkers7.3%→3.5%−3.7%p此前近期
- Prostate Cancer Treatment and Research2.8%→0.0%−2.8%p此前近期
- Cancer survivorship and care8.5%→5.9%−2.5%p此前近期
- Global Cancer Incidence and Screening10.5%→8.0%−2.5%p此前近期
近期高频术语
近期论文标题中相较以往显著增加的表述。
作者国家构成
将近 24 个月(2024-09 – 2026-08)与此前 24 个月(2022-09 – 2024-08)并列显示。
- US59.5%→51.8%−7.7%p此前近期
- GB6.4%→9.9%+3.5%p此前近期
- CA11.9%→9.2%−2.7%p此前近期
- FR5.3%→7.4%+2.0%p此前近期
- CN4.9%→6.1%+1.2%p此前近期
- NL0.0%→5.7%+5.7%p此前近期
机构发文 Top 5
2018 – 2026 期间在该期刊发表论文的前 5 家机构。
近期发表论文
20按发表日期最新的 20 篇,并非全部。
高被引论文
202018 – 2026 期间被引最高的 20 篇。
数据截至 2026-09-05